Anita Nutikka
Overview
Explore the profile of Anita Nutikka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
176
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tam P, Mahfoud R, Nutikka A, Khine A, Binnington B, Paroutis P, et al.
J Cell Physiol
. 2008 May;
216(3):750-63.
PMID: 18446787
Although verotoxin-1 (VT1) and verotoxin-2 (VT2) share a common receptor, globotriaosyl ceramide (Gb(3)), VT2 induces distinct animal pathology and is preferentially associated with human disease. Moreover VT2 cytotoxicity in vitro...
2.
Khine A, Tam P, Nutikka A, Lingwood C
Glycobiology
. 2004 Apr;
14(8):701-12.
PMID: 15102715
In verotoxin 1 (VT1)-sensitive cells, globotriaosyl ceramide (Gb3) bound VT1 is endocytosed and transported retrogradely to the Golgi/endoplasmic reticulum (ER). The importance of the Golgi-dependent retrograde transport of VT1 is...
3.
Nutikka A, Lingwood C
Glycoconj J
. 2004 Feb;
20(1):33-8.
PMID: 14973368
Purified renal globotriaosyl ceramide (Gb3)/cholesterol mixtures sonicated heated in a Triton-containing buffer placed below a discontinuous sucrose gradient form glycosphingolipid (GSL)-containing dense lipid structures at the 30/5% sucrose interface after...
4.
Chark D, Nutikka A, Trusevych N, Kuzmina J, Lingwood C
Eur J Biochem
. 2004 Jan;
271(2):405-17.
PMID: 14717708
The role of renal expression of the glycosphingolipid verotoxin receptor, globotriaosylceramide, in susceptibility to verotoxin-induced hemolytic uremic syndrome is unclear. We show that a single glycosphingolipid can discriminate multiple specific...
5.
Nutikka A, Binnington-Boyd B, Lingwood C
Methods Mol Med
. 2002 Oct;
73:197-208.
PMID: 12375430
No abstract available.
6.
Nutikka A, Binnington-Boyd B, Lingwood C
Methods Mol Med
. 2002 Oct;
73:187-95.
PMID: 12375429
No abstract available.
7.
Binnington B, Lingwood D, Nutikka A, Lingwood C
Neurochem Res
. 2002 Oct;
27(7-8):807-13.
PMID: 12374217
Variation in the lipid moiety of the verotoxin (VT) receptor glycosphingolipid, globotriaosyl ceramide (Gb3) can modulate toxin binding. The binding of VT1 and VT2 to C18 and C22 alpha hydroxy...
8.
Salhia B, Rutka J, Lingwood C, Nutikka A, van Furth W
Neoplasia
. 2002 Jun;
4(4):304-11.
PMID: 12082546
Malignant meningiomas (MMs) are aggressive intracranial neoplasms with a 75% 5-year recurrence rate. Verotoxin 1 (VT1) is an Escherichia coli toxin, which has recently been shown to have anti-neoplastic action...
9.
Hoey D, Currie C, Else R, Nutikka A, Lingwood C, Gally D, et al.
J Med Microbiol
. 2002 Feb;
51(2):143-149.
PMID: 11865842
Human enterohaemorrhagic Escherichia coli (EHEC) infection most commonly arises, either directly or indirectly, from cattle, which act as a reservoir host for these bacteria. In man, EHEC disease can be...